Jan Stöhlmacher
Dresden University of Technology
4 Papers
18 Citations
Jan Stöhlmacher is an academic researcher from Dresden University of Technology. The author has contributed to research in topics: Lung cancer & Antigen. The author has an hindex of 4, co-authored 4 publications.
Chat about Author
Papers
A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer
Martin Sebastian,Martin Sebastian,Andreas Schröder,Birgit Scheel,Henoch S. Hong,Anke Muth,Lotta von Boehmer,Lotta von Boehmer,Alfred Zippelius,Frank Mayer,Martin Reck,Djordje Atanackovic,Michael Thomas,Folker Schneller,Jan Stöhlmacher,Helga Bernhard,Andreas Gröschel,Thomas Lander,Jochen Probst,Tanja Strack,Volker Wiegand,Ulrike Gnad-Vogt,Karl-Josef Kallen,Ingmar Hoerr,Florian Von Der Muelbe,Mariola Fotin-Mleczek,Alexander Knuth,Alexander Knuth,Sven D. Koch +28 more
TL;DR: CV9201 was well-tolerated and immune responses could be detected after treatment supporting further clinical investigation, and antigen-specific immune responses against ≥ 1 antigen were detected in 63% of evaluable patients after treatment.
156
Pharmacogenetics in gastrointestinal tumors.
TL;DR: The pharmacogenetic approach to individualize therapy in gastrointestinal cancers is promising, but additional larger and controlled studies are needed to justify changes of treatment strategies.
19
Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer.
Alexander Stein,Djordje Atanackovic,Bert Hildebrandt,Patrick Stübs,Wolfram Brugger,Gunnar Hapke,Claus Christoph Steffens,Gerald Illerhaus,Ernst Bluemner,Jan Stöhlmacher,Carsten Bokemeyer +10 more
TL;DR: FOLFOXIRI+BEV was feasible in this molecularly unselected mCRC patient population, showing a high efficacy in terms of survival, overall response and secondary resection rate and pharmacogenomic profiling revealed no clinically relevant marker.
A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer
Gerald Schmid-Bindert,Walburga Engel-Riedel,Martin Reck,Wolfgang Schuette,Jan Stöhlmacher,Jürgen Fischer,Julien Mazieres,Christos Chouaid,Martin Wolf,Nuria Viñolas,Victoria Soldatenkova,Veronique Ripoche,Tuan Nguyen,Carla Visseren-Grul +13 more
TL;DR: Although the study did not meet the primary objective, both treatment groups demonstrated good safety-related feasibility and tolerability as adjuvant treatment in patients with completely resected Stage IB/II NSCLC.